An Open-Label, Multicenter, Phase 1/2 Study of Tazemetostat (EZH2 Histone Methyl Transferase [HMT] Inhibitor) as a Single Agent in Subjects With Advanced Solid Tumors or With B-cell Lymphomas and Tazemetostat in Combination With Prednisolone in Subjects With Diffuse Large B Cell Lymphoma
Latest Information Update: 28 Mar 2024
At a glance
- Drugs Prednisolone (Primary) ; Tazemetostat (Primary) ; Midazolam
- Indications B-cell lymphoma; Diffuse large B cell lymphoma; Follicular lymphoma; Non-Hodgkin's lymphoma; Solid tumours
- Focus Adverse reactions; First in man; Proof of concept; Therapeutic Use
- Sponsors Eisai Co Ltd; Epizyme
- 14 Dec 2021 Results presented at the 63rd American Society of Hematology Annual Meeting and Exposition
- 12 Dec 2021 According to Epizyme media release, data from this study presented at the 2021 American Society of Hematology (ASH) Annual Meeting.
- 15 Nov 2021 Status changed from active, no longer recruiting to completed.